Literature DB >> 7246129

The incidence of coeliac disease in children in south-east Sweden.

L Stenhammar, C G Johansson.   

Abstract

Among children born between 1969 and 1977 in two areas of south-east Sweden an initial flat small intestinal mucosa was found in 84 cases, 64 of whom were considered to have coeliac disease (CD) diagnosed mostly according to the criteria formulated by the European Society for Paediatric Gastroenterology and Nutrition. The incidence of CD was 1/859, which is in agreement with that of a recent report from south Sweden. This suggests that the incidence of CD is the same in the whole of Sweden. In the present study all patients with an initial flat mucosa improved clinically and histologically after 1 year or more on a gluten-free diet. When challenged with gluten, 19% did not relapse within 2 years, thus fulfilling the criteria for so-called transient gluten intolerance. These patients had a lower mean age of symptom debut and for first biopsy, compared with the patients with CD.

Entities:  

Mesh:

Year:  1981        PMID: 7246129     DOI: 10.1111/j.1651-2227.1981.tb16567.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  4 in total

1.  Increasing incidence of coeliac disease in Sweden.

Authors:  H Ascher; I Krantz; B Kristiansson
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

2.  Incidences of childhood coeliac diseases and transient gluten intolerance move discrepantly in UK and Sweden.

Authors:  L Stenhammar; P Ansved; G Jansson; V Jansson
Journal:  Arch Dis Child       Date:  1987-10       Impact factor: 3.791

3.  Similar prevalence of coeliac disease in children and middle-aged adults in a district of Sweden.

Authors:  C Hallert; R Gotthard; G Jansson; K Norrby; A Walan
Journal:  Gut       Date:  1983-05       Impact factor: 23.059

4.  Immune response patterns in coeliac disease. Serum antibodies to dietary antigens measured by an enzyme linked immunosorbent assay (ELISA).

Authors:  H Scott; O Fausa; J Ek; P Brandtzaeg
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.